FireCyte Therapeutics
United States · $12.0M raised
- Employees
- 1–10
- Business Model
- B2B
- Website
- firecyte.com
- Total Funding
- $12.0M
- Last Round
- $6.5M Venture RoundJan 2022
- Rounds
- 2
About
Neuroscience-based ophthalmology company developing multi-target intravitreal anti-inflammatory proteins.
Summary
FireCyte Therapeutics is a Biotech company based in United States. It has raised $12.0M in total across 2 rounds, most recently a $6.5M Venture Round round in Jan 2022. Investors include Morningside Group, AbbVie Ventures and Mass General Brigham Ventures.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.